Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Prospektīvs randomizēts klīniskais pētījums× | Adaptīvs randomizēts klīniskais pētījums× | |
|---|---|---|
| Nozare | Epidemioloģija | Epidemioloģija |
| Saime | Process / pipeline | Process / pipeline |
| Izcelsmes gads≠ | 1948 (landmark MRC streptomycin trial) | Late 1990s–2000s (widespread adoption post-2010) |
| Autors≠ | Austin Bradford Hill / Medical Research Council | Donald Berry and colleagues; formalized by FDA guidance in 2010 and 2019 |
| Tips≠ | Experimental / interventional study design | Experimental clinical trial design |
| Pirmavots≠ | Medical Research Council (1948). Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. British Medical Journal, 2(4582), 769–782. link ↗ | Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36. DOI ↗ |
| Citi nosaukumi | Prospective RCT, randomized controlled trial, RCT, controlled clinical trial | adaptive RCT, adaptive trial design, response-adaptive randomization trial, adaptive clinical trial |
| Saistītās≠ | 5 | 6 |
| Kopsavilkums≠ | A prospective randomized clinical trial (RCT) is an experimental study in which participants are assigned to intervention or control groups by chance before any outcomes are observed, then followed forward in time. Random allocation eliminates systematic selection bias, making this design the gold standard for establishing causal efficacy of treatments in medicine and clinical research. | An adaptive randomized clinical trial (adaptive RCT) is a prospective experimental study that uses pre-specified rules to modify one or more trial aspects — such as sample size, allocation ratios, or treatment arms — based on accumulating data collected during the trial itself, while maintaining statistical validity and integrity of the study. |
| ScholarGateDatu kopa ↗ |
|
|